Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,880 matching trials from the live ClinicalTrials.gov search.
Conditions
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions
Nivolumab, (8gy x 3), Platinum Doublet
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
Conditions
Pain, Postoperative, Medication Adherence, Opioid Use, Knowledge, Attitudes, Practice, Risk Reduction Behavior
Interventions
Educational Intervention, Nudge
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 99 Years
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Newly Diagnosed Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib, Dexamethesone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Rapid UTI Diagnostics in Lower Urinary Tract Dysfunction Among Catheter Users

NCT07784829
Conditions
Neurogenic Bladder Disorder, Lower Urinary Tract Disorder, Urinary Tract Infection (Diagnosis)
Interventions
urine Resazurin Reduction Ratio, USQNB
Diagnostic Test · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Glanzmann Thrombasthenia
Interventions
EPTACOG BETA
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
HPV, Throat Cancer, Oropharyngeal Carcinoma, Oropharyngeal Cancer, Human Papilloma Virus
Interventions
18 F-FMISO PET/CT, Radiation, Cisplatin, Carboplatin, 5-fluorouracil
Diagnostic Test · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Sarcoma
Interventions
Trabectedin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more
Terminated Phase 1 Interventional Results available

Camostat With Bicalutamide for COVID-19

NCT04652765
Conditions
Covid19, SARS-CoV Infection, Coronavirus Infection
Interventions
Camostat Mesilate, Bicalutamide 150 mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Vasospasm
Interventions
Cervical Sympathetic Block (bupivicaine, clonidine)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Osteosarcoma, Leukemia, Lymphoma
Interventions
glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin
Drug
Lead sponsor
BTG International Inc.
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 20 more
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Surgical Procedure
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor
Interventions
Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate, 177Lu-Dotatate
Device · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Terminated Phase 2 Interventional Results available

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

NCT05009979
Conditions
Hepatocellular Carcinoma
Interventions
F18-FDG, MRI, CT, F18-DCFPyL, Tumor biopsy
Drug · Device · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hypertension, Pregnancy-Induced, Postpartum Preeclampsia, Hypertension; Maternal
Interventions
Blood Pressure Control Targets, Hypertension Management
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Retroperitoneal Sarcoma
Interventions
Liposomal Bupivacaine, Quadratus Lumborum Block, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Bleeding Disorders, Iron, Platelet, Bleeding
Interventions
IV Iron (standard of care)
Drug
Lead sponsor
Nicoletta C Machin
Other
Eligibility
15 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Terminated Not applicable Interventional

Nightmare Rescripting and Rehearsal

NCT04529070
Conditions
Nightmare, Sleep
Interventions
Nightmare Rescripting and Rehearsal, standard of care
Behavioral
Lead sponsor
David Moss
Federal
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Conditions
Achilles Injuries Tendon, Achilles Tendinopathy (AT), Achilles Tendinitis, Left Leg, Achilles Tendinitis, Right Leg, Achilles Tendon Pain, Achilles Tendonitis
Interventions
Platelet Rich Plasma, Extracorporeal Shockwave Therapy, Sham PRP, Sham ESWT
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cambridge, Massachusetts
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Nutrition and Body Composition in Acute Lymphoblastic Leukemia

NCT01317940
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Vitamin D Deficiency
Interventions
Vitamin D and Calcium Citrate
Dietary Supplement
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 29 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Tumor Infiltrating Lymphocyte, CD8-PET, Advanced Melanoma
Interventions
Crefmirlimb, PET/CT imaging
Drug · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Kidney Transplant; Complications, CMV
Interventions
Letermovir 480 mg once daily, Historical/Control
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
COVID-19
Interventions
GAMUNEX-C, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more
Conditions
Hydrocephalus in Infants
Interventions
Non-Invasive Pressure Monitor
Device
Lead sponsor
Indiana University
Other
Eligibility
0 Months to 12 Months
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana